INTERVIEW: Bioabsorbable Stents? No, Drug-Filled Stents Is Way Forward, Says Medtronic Cardiac Intervention CMO
This article was originally published in Clinica
The world’s largest medtech pureplay, Medtronic, believes drug-filled stents will be a major advance in coronary stent technology, which is why it is bypassing bioabsorable technologies like Abbott’s Absorb BVS stent and planning its next steps toward bringing DFSs to market.
Register for our free email digests: